View More Recent Stories

Jan 7, 2025 08:02AM Rezolute (RZLT) Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Dec 4, 2024 06:01AM BTIG Reiterates Neutral Rating on Rezolute (RZLT)

Dec 3, 2024 08:00AM Rezolute Inc. (RZLT): FDA Grants Orphan Drug Designation to Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Nov 8, 2024 07:16AM Rezolute, Inc. (RZLT) Tops Q1 EPS by 9c

Sep 27, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Sep 20, 2024 11:55AM Jones Trading Reiterates Buy Rating on Rezolute (RZLT)

Sep 20, 2024 05:22AM BTIG Reiterates Buy Rating on Rezolute (RZLT)

Sep 10, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Sep 9, 2024 11:58AM Rezolute (RZLT) PT Raised to $15 at BTIG

Sep 9, 2024 08:38AM Jones Trading Reiterates Buy Rating on Rezolute (RZLT) following FDA lift of clinical hold on RZ358

Sep 9, 2024 07:30AM Rezolute Inc. (RZLT): FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Aug 5, 2024 05:02PM Rezolute Inc. (RZLT) Files for 4.5M Share Offering by Selling Stockholders

Aug 5, 2024 07:30AM Rezolute Inc. (RZLT) Announces FDA Clearance of IND Application for Phase 3 Study of RZ358

Jul 17, 2024 06:07AM BTIG Starts Rezolute (RZLT) at Buy

Jun 27, 2024 08:02AM Rezolute (RZLT) Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Jun 13, 2024 04:01PM Rezolute Inc. (RZLT) Announces Proposed Share and Warrant Offering

View More Recent Stories